Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  isotretinoin
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-11 of 11 for your search:
Start Over
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2009-01064, CDR0000069018, COG-ANBL0032, ANBL0032, U10CA180886, U10CA030969, U10CA098543, COG-P9842, NCT00026312
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 20 at diagnosis
Sponsor: Other
Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719
European Low and Intermediate Risk Neuroblastoma Protocol
Phase: Phase III
Type: Treatment
Status: Active
Age: 90 days to 18 years
Sponsor: Other
Protocol IDs: LINES, NCT01728155
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 17 months and under
Sponsor: NCI, Other
Protocol IDs: ANBL1232, NCI-2014-00677, U10CA098543, U10CA180886, NCT02176967
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: 012010, 2009-018077-31, NCT01701479
Therapy for Children With Advanced Stage Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 19
Sponsor: Other
Protocol IDs: NB2012, NCI-2013-00034, NCT01857934
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Under 18
Sponsor: Other
Protocol IDs: HSJD-HR-NB-Ch14.18, NCT02169609
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-02011, N2011-04, NANT 11-04, CDR0000741991, NANT 2011-04, NANT N2011-04, P01CA081403, NCT01711554
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: ANBL09P1, NCI-2011-01745, CDR0000682629, U10CA180886, U10CA098543, COG-ANBL09P1, NCT01175356
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: 2011OC072, MT2011-11C, NCT01526603
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 13-260, NCT02100930
Start Over